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Abstract 
Background: Whether body composition is associated with the N‑terminal pro‑B‑type natriuretic peptide (NT‑
proBNP) level and its prognostic performance in acute coronary syndrome (ACS) remains unknown. We aimed to 
investigate the influence of body composition on the NT‑proBNP level and its prognostic performance among ACS 
patients.
Methods: In total, 1623 ACS patients with NT‑proBNP data were enrolled. Percent body fat and lean mass index 
were estimated using the Clínica Universidad de Navarra—Body Adiposity Estimator equation. Patients were divided 
into three groups according to the tertiles of sex‑specific body mass index, percent body fat, or lean mass index. The 
endpoints were death from any cause and cardiovascular death.
Results: Body mass index was inversely correlated with NT‑proBNP levels (β = −0.036, P = 0.003). Lean mass index, 
but not percent body fat, was inversely associated with NT‑proBNP levels (β of lean mass index = −0.692, P = 0.002). 
During a median follow‑up of 23 months, 161 all‑cause deaths occurred, and of these, 93 (57.8 %) were attributed to 
cardiovascular causes. Multivariate Cox analysis showed that the NT‑proBNP level independently predicted all‑cause 
mortality or cardiovascular death in the lower body mass index, lean mass index, and percent body fat groups. How‑
ever, the prognostic performance of NT‑proBNP was attenuated in patients with high body mass index, lean mass 
index, and percent body fat. In the subgroup of patients with diabetes, inverse associations between NT‑proBNP levels 
and body mass index or body composition were not observed. In addition, the negative influence of high body mass 
index and body composition on the prognostic performance of the NT‑proBNP level appeared to be attenuated.
Conclusions: Body mass index and lean mass index, but not percent body fat, are inversely associated with NT‑
proBNP levels. The prognostic performance of this biomarker may be compromised in patients with high body mass 
index, percent body fat, or lean mass index. Additionally, the influence of body composition on the NT‑proBNP level 
and its prognostic performance might be attenuated in diabetic patients with ACS.
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Background
During the past decade, obesity has become a large 
public health problem. A previous study reported that 
the combined prevalence of obesity and overweight has 
increased by nearly 50 % from 1992 to 2008 in China [1]. 
A growing number of patients with obesity are at high 
risk for acute coronary syndrome (ACS) owing to com-
mon risk factors, such as diabetes, dyslipidemia, hyper-
tension, and systemic inflammation. N-terminal pro-B 
type natriuretic peptide (NT-proBNP) is a widely used 
biomarker, and it has shown robust prognostic poten-
tial in ACS [2, 3]. An unexpected inverse relationship 
between BNP/NT-proBNP levels and body mass index 
(BMI) has been documented in both healthy individu-
als and in patients with heart failure [4], and low NT-
proBNP cut-off levels are recommended in the diagnosis 
of heart failure among obese patients [5]. However, only 
two studies have investigated the relationship between 
the prognostic relevance of NT-proBNP and BMI in 
ACS patients [6, 7], and the findings of these two stud-
ies were contradictory. Lorgis et al. [6] suggested that the 
prognostic performance of NT-proBNP was attenuated 
in patients with high BMI, while Choi et  al. [7] found 
that the prognostic performance of NT-proBNP was 
high in patients with high BMI.
BMI does not consider body composition and fat dis-
tribution; therefore, the use of BMI as a measure of 
obesity has been questioned recently [8, 9]. Body com-
position considers fat mass and lean mass that includes 
the muscles, skeleton, and body fluids. Percent body fat 
(%BF) and the lean mass index (LMI) have been shown 
to be more accurate indicators to measure obesity [8, 
10]. Additionally, Das et al. [11] showed that natriuretic 
peptide (NP) levels were better associated with lean mass 
than with BMI in a healthy population. Nevertheless, the 
association of body composition with the NT-proBNP 
level and its prognostic performance in patients with 
ACS remains unknown. In the present study, we aimed to 
investigate the influence of body composition on the NT-
proBNP level and its prognostic performance in patients 
with ACS. As obesity is generally accompanied with 
diabetes, we further investigated the influence of body 
composition on the NT-proBNP level and its prognostic 
performance in diabetic patients with ACS.
Methods
Patients
The present study used data from the West China Hos-
pital coronary artery disease (CAD) database. This data-
base has been described in detail previously [12]. In brief, 
the database included the data of consecutive patients 
suspected to have coronary artery disease and those who 
underwent coronary angiography between July 2008 and 
September 2012. The database prospectively collected 
demographic, clinical, laboratory, and treatment data of 
patients. The inclusion criteria of the present study were 
as follows: angiographic evidence of 50 % stenosis in ≥1 
coronary artery with symptoms, electrocardiography or 
cardiac biomarker criteria consistent with ACS, presence 
of complete BMI data, and presence of complete follow-
up information. The study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki and 
was approved by the institutional review board of West 
China Hospital, Sichuan University (approval number 
2012-243). All participants provided informed consent.
Body composition assessment
During hospitalization, body height and weight of the 
patients were measured by nurses using standard meth-
ods. BMI was calculated as weight (kg) divided by the 
square of height (m2). Body fat (BF) was estimated using 
the Clínica Universidad de Navarra—Body Adiposity 




sex is replaced by 0 for male and 1 for female individuals 
[13]. This formula has been validated in a large popula-
tion [14]. The lean mass index was calculated as follows: 
(1 − %BF) × BMI kg/m2 [9]. As no reference value has 
been reported in a Chinese population, we divided the 
study patients into three groups according to the tertiles 
of sex-specific BMI, LMI, or BF.
Baseline data collection
The baseline anthropometric and blood pressure data 
were collected by nurses. The medical history (history 
of hypertension, diabetes  mellitus, dyslipidemia, heart 
failure, cerebrovascular accident, and myocardial infarc-
tion), smoking history, vital signs at admission, echo-
cardiographic data (left ventricular ejection fraction and 
left ventricular end-diastolic volume), and final diagnosis 
were obtained from hospital records and via interviews. 
In the present study, a patient was considered to have 
diabetes mellitus if the fasting plasma glucose level, 2-h 
plasma glucose level after a 75-g oral glucose tolerance 
test, or hemoglobin A1c level satisfied the ADA criteria 
at the time of presentation, diabetes was diagnosed by a 
previous physician, and/or the patient was using insu-
lin or oral hypoglycemic agents. The Killip class and risk 
stratification of ACS based on the thrombolysis in myo-
cardial infarction (TIMI) risk score for NSTE-ACS or 
STEMI were evaluated by physicians according to the 
presentation characteristics.
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Laboratory measurements
Venous blood samples were collected in tubes contain-
ing EDTA and analyzed at the Department of Labora-
tory Medicine, West China Hospital, accredited by the 
College of American Pathologists. Plasma NT-proBNP 
and TnT levels were measured using an electrochemilu-
minescence immunoassay kit (Roche Diagnostics, Gren-
zach Wyhlen, Germany). The NT-proBNP results were 
obtained within the first few days after symptom onset 
in all of the study patients. The NT-proBNP reference 
levels in a healthy population depend on age and sex. 
In male individuals, the 95th percentile level increases 
from 83.9  pg/mL at 45–54  years of age to 486  pg/mL 
at  ≥75  years of age. In female individuals, the level 
increases from 169 to 738 pg/mL. The peak plasma TnT 
level during hospitalization was used in the analysis. The 
chronic kidney disease epidemiology (CKD-EPI) equa-
tion was used to determine the estimated glomerular fil-
tration rate (eGFR).
Endpoint definition and follow‑up
The endpoints were death from any cause and cardio-
vascular death. Follow-up information was obtained by 
contacting patients and/or their relatives via letters or the 
telephone, or through outpatient visits. All data were cor-
roborated with hospital records.
Statistical analysis
Baseline data are presented as median (with 25th and 
75th percentiles) or counts and proportions. The Chi 
square test or Fisher’s exact test was used to compare 
categorical variables across different age groups. The 
Kolmogorov–Smirnov test was used to assess the dis-
tribution of the data. If the data followed normal distri-
bution, the data were compared using one-way analysis 
of variance; otherwise, the data were compared using 
the Kruskal–Wallis test. Because the NT-proBNP data 
followed non-normal distribution, the data were log-
transformed for multivariate analysis. Considering the 
presence of right-censored limits of NT-proBNP levels 
because of the detection threshold (≤35000  pg/mL), a 
multiple Tobit linear regression analysis was performed 
to precisely quantify the association between log-trans-
formed NT-proBNP data and other factors. Potential 
covariates were entered into the model if they had a 
univariate P value  <0.10. To determine the association 
between NT-proBNP levels and outcomes, Kaplan–
Meier plots by tertiles of NT-proBNP levels were con-
structed in different body composition strata. Then, Cox 
proportional hazard analyses were performed to identify 
the prognostic impact of log NT-proBNP levels stratified 
according to BMI and body composition. The following 
variates were included in the multivariate model: age, 
sex, LVEF, eGFR, Killip >1, TIMI risk score, medical his-
tory (previous MI, heart failure, and hypertension) and 
medications at discharge. The assumption of propor-
tional hazards was assessed on the basis of the methods 
described by Grambsch and Therneau [15]. Model cali-
bration was evaluated using the Gronnesby and Borgan 
test [16]. To assess differences between the Cox regres-
sion coefficients of NT-proBNP of the body composition 
strata, the z test was performed as described previously 
[17]. All statistical analyses were performed using Stata/
MP 13.0. A two-side P value <0.05 was considered statis-
tically significant.
Results
Of 2251 patients with ACS enrolled into the West China 
Hospital CAD database, 1623 patients had complete data 
on NT-proBNP and BMI for analysis in the present study. 
The baseline characteristics of the patients are shown in 
Table 1. Age was significantly lower among patients with 
a high BMI or LMI than among those with a low BMI or 
LMI. In contrast, age and the number of risk factors for 
coronary artery disease were significantly higher among 
patients with a high BF amount than among those with a 
low BF amount.
The association between NT-proBNP levels and BMI 
or body composition in the ACS patients is illustrated 
in Fig.  1. The plasma NT-proBNP levels significantly 
decreased with the increase in BMI and LMI (P = 0.001 
and P  <  0.001, respectively); however, no such decrease 
was noted with the increase in the BF amount (P = 0.608; 
Fig.  1). In multivariate Tobit linear regression analysis 
with only BMI as the measure of obesity in model 1, BMI 
as a continuous variable was inversely associated with log 
NT-proBNP levels, and when LMI and BF were added 
into model 1, only LMI showed an independent inverse 
correlation with NT-proBNP levels. Additionally, similar 
results were obtained when BMI, LMI, and BF were con-
sidered as categorical variables (Table 2).
Over a median follow-up of 23  months (interquartile 
range, 16–34  months; maximum follow-up, 5.5  years), 
161 all-cause deaths occurred, and of these, 93 (57.8 %) 
were attributed to cardiovascular causes. Kaplan–Meier 
plots showed that the NT-proBNP tertiles were associ-
ated with an increased risk of mortality in all the BMI, 
LMI, and BF strata (all log-rank P and P for trend <0.001 
in each group; Fig.  2). In terms of all-cause death, mul-
tivariate Cox analysis showed that the NT-proBNP level 
was an independent predictor of mortality in the 1st and 
2nd BMI, LMI, and BF tertiles. However, the prognostic 
value of the NT-proBNP level was not statistically sig-
nificant in the high BMI, LMI, and BF groups (Fig.  3). 
The goodness of fit of the multivariate model was satis-
factory (P = 0.21). With regard to cardiovascular death, 
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the multivariate Cox analysis showed a significant asso-
ciation between the NT-proBNP level and cardiovas-
cular death among patients with low BMI, LMI, and 
BF amount, whereas the association was absent among 
patients with high BMI, LMI, and BF amount (Fig. 3). The 
goodness of fit of the multivariate model was satisfactory 
(P = 0.61), and there was no significant violation of the 
proportional hazards assumption (P = 0.12 for all cause 
death and P = 0.06 for cardiovascular death).
In the subgroup of patients with diabetes, inverse asso-
ciations between NT-proBNP levels and BMI or body 
composition were not observed (Fig. 4). In addition, the 
negative influence of high BMI and body composition 
on the prognostic performance of the NT-proBNP level 
appeared to be attenuated (Fig. 5).
Discussion
The present study found an inverse association between 
BMI and NT-proBNP levels in patients with ACS. Fur-
thermore, when body composition was considered, LMI, 
but not BF, was inversely associated with NT-proBNP 
levels. The prognostic performance of the NT-proBNP 
level in patients with ACS was compromised among 
patients with high BMI, LMI, or BF. However, the influ-
ence of BMI and body composition on the NT-proBNP 
level and its prognostic performance appeared to be 
attenuated in diabetic patients with ACS. To our knowl-
edge, this is the first study to investigate the association 
between body composition and the prognostic perfor-













































































Fig. 1 NT‑proBNP levels across the BMI (a), LMI (b), and BF (c) groups. The NT‑proBNP levels decreased as the BMI (a) and LMI (b) increased. The 
NT‑proBNP levels did not differ across the BF tertiles (c). NT-proBNP N‑terminal‑pro B‑type natriuretic peptide; BMI body mass index; LMI lean mass 
index; BF body fat
Table 2 Multivariable Tobit linear regression for  Log NT-
proBNP as dependent variable
BMI, LMI, and BF are considered as continuous variables in model 1 and model 2 
and considered as categorical variables in model 3 and model 4
Those models are adjusted for age, sex, LVEF, LVEDV, CKD-EPI, Killip >1, heart rate 
at admission, AMI, peak troponin, and previous MI
Abbreviations as in Table 1
a  Reference is the 1st tertile
β(SE) P value
Model 1
 BMI (kg/m2) −0.036 (0.012) 0.003
Model 2
 BMI (kg/m2) 0.046 (0.081) 0.575
 LMI (kg/m2) −0.692 (0.218) 0.002
 BF (%) 0.154 (0.091) 0.091
Model 3
 BMI
  2nd BMI tertilea −0.240 (0.089) 0.007
  3rd BMI tertilea −0.259 (0.092) 0.005
Model 4
 BMI
  2nd BMI tertilea 0.023 (0.155) 0.882
  3rd BMI tertilea 0.098 (0.236) 0.680
 LMI
  2nd LMI tertilea −0.384 (0.147) 0.009
  3rd LMI tertilea −0.533 (0.213) 0.012
 BF
  2nd BF tertilea 0.024 (0.123) 0.845
  3rd BF tertilea 0.092 (0.193) 0.633
Page 7 of 11Huang et al. Cardiovasc Diabetol  (2016) 15:58 
Myocardial ischemia and hypoxia have been shown to 
directly induce an increase in the expression of proBNP, 
even in the absence of left ventricular dysfunction [18]. 
It has been reported that NT-proBNP levels are high 
across the entire spectrum of CADs and the increase in 
associated with CAD severity [19, 20]. Additionally, the 
angiographic severity of CAD has been shown to be bet-
ter reflected by the NT-proBNP level than the BNP level 
[21]. Several studies have validated the prognostic per-
formance of the NT-proBNP level in patients with ACS, 
which was independent of LVEF, troponin, and renal 
insufficiency [2, 3]. Thus, NT-proBNP has been proposed 
as a promising biomarker for the early diagnosis of ACS 
[22] and its risk stratification [23–25].
However, the true implications of NT-proBNP in clini-
cal practice were typically influenced by confounders, 
such as age, sex, diabetes, and renal function. Recently, 
a study showed that BMI was inversely associated 
with BNP/NT-proBNP levels [4]. Some of the possible 
explanations for this phenomenon include an increase in 
the clearance of natriuretic peptide by the C-type natriu-
retic peptide receptor [26], impairment of the natriuretic 
peptide response termed “natriuretic peptide handicap” 
[27], and compromised detection of NT-proBNP in 
obese individuals [28]. However, some of these hypoth-
eses have been contradicted [11]. Therefore, the exact 
mechanism underlying the negative association between 
NPs and obesity remains undefined. A previous study 
proposed a bidirectional relationship between BNP and 
adiposity because BNP has been shown to cause lipoly-
sis via A-type natriuretic peptide receptor [5]. Addi-
tionally, Li et  al. [29] recently suggested that changes 
in liraglutide-induced lean mass and body fat were 
associated with increases in plasma NP levels in obese 
type 2 diabetic patients. However, our finding that the 
NT-proBNP levels differ across LMI tertiles, but not 
BF tertiles, in patients with ACS does not support this 
hypothesis. In fact, previous studies by Das et  al. and 
Fig. 2 Kaplan–Meier plots according to the NT‑proBNP tertiles across the BMI, LMI, and BF tertiles. Kaplan–Meier plots showing that the NT‑proBNP 
tertiles are associated with an increased risk of mortality in all BMI, LMI, and BF strata. NT-proBNP N‑terminal‑pro B‑type natriuretic peptide; BMI body 
mass index; LMI lean mass index; BF body fat
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Oreopoulos et  al. [8, 11] showed that a high LMI, but 
not BF, was associated with low BNP/NT-proBNP levels 
in both the general population and a chronic heart fail-
ure population. In the present study, these findings were 
extended to patients with ischemic heart disease. Chang 
et  al. provided a plausible explanation for this finding. 
The authors demonstrated that free testosterone was a 
mediator of the association between lean mass and NPs 
through an increase in lean mass and a decrease in NP 
synthesis; however, estradiol, which plays an important 
role in the regulation of adiposity [30], does not appear 
to influence NP levels [31].
a b c
d e f
Fig. 3 HRs of log NT‑proBNP levels considered as continuous variables for both outcomes in the body composition subgroups. The prognostic 
performance of the NT‑proBNP level for all‑cause mortality (a–c) and cardiovascular death (d–f) is attenuated with increasing BMI, LMI, and BF. HR 





































































Fig. 4 NT‑proBNP levels across the BMI (a), LMI (b), and BF (c) groups among the diabetic subgroups. Inverse associations between NT‑proBNP 
levels and increased BMI or body composition are not observed in the diabetic patients. NT-proBNP N‑terminal‑pro B‑type natriuretic peptide; BMI 
body mass index; LMI lean mass index; BF body fat
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Although numerous studies focused on the associa-
tion between BMI and NT-proBNP levels, few studies 
have evaluated whether BMI influences the prognostic 
performance of NT-proBNP in heart diseases, especially 
ACS. Choi et al. performed a study of 2736 Koreans with 
acute myocardial infarction (AMI) and showed that NT-
proBNP levels were lower in obese AMI patients than in 
non-obese AMI patients and that NT-proBNP was an 
independent prognostic factor in obese AMI patients. 
However, it should be pointed out that these authors did 
not assess the goodness of fit and overall performance of 
the logistic regression models [7]. Considering that NT-
proBNP in the multivariate model unreasonably failed to 
predict outcomes in the normal group (P =  0.113), the 
calibration of the model was very likely to not be good. 
Thus, the results were not convincing. On the contrary, 
Lorgis et  al. addressed this issue in a prospective study 
of 2217 AMI patients. The authors used the WHO BMI 
classification system to classify the extent of obesity in 
the patients and showed that log NT-proBNP indepen-
dently predicted 1-year cardiovascular mortality in nor-
mal and overweight patients. However, in obese patients, 
the propeptide levels failed to retain their prognostic 
value (OR = 1.34, P = 0.244). The goodness of fit of the 
final model was good [−2log-likelihood: 642; P (Hosmer–
Lemeshow) = 0.479] [6]. Our results from the BMI sub-
groups extended the findings of the study by Lorgis et al. 
to the entire spectrum of ACS covering unstable angina.
It is believed that low BNP/NT-proBNP levels are good 
for prognosis [10]. As obese patients have low BNP/NT-
proBNP levels, this perspective appears to mirror the obe-
sity paradox in which obesity has a paradoxical survival 
benefit [32]. However, the paradox has been almost exclu-
sively documented in studies that use BMI as a measure of 
obesity. Oreopoulos et al. [8] suggested that BMI, as a sur-
rogate for obesity, was better correlated with lean mass than 
body fat. Obesity indexed by BMI may sometimes indicate 
excessive muscle rather than excessive fat. Additionally, a 
previous study has suggested that lean mass, but not body 
fat, can predict all-cause death in patients with coronary 
artery disease [12]. Therefore, in the present study, we 
divided patients according to body compositions in order 
to accurately evaluate the influence of true obesity on the 
prognostic performance of NT-proBNP. Low NT-proBNP 
levels were observed in patients with high LMI, but not 
in those with high BF, and the prognostic performance of 
NT-proBNP was significantly compromised in patients 
with high LMI and high BF. These findings suggest that 
it is not plausible to simply assume that low NT-proBNP 
levels reflect mild disease severity in obesity. In fact, early 
studies have suggested that BNP/NT-proBNP levels failed 
to reflect LV filling pressure in obese individuals, indicating 
that BNP/NT-proBNP should not be considered as a sur-
rogate for disease severity in obese patients [33].
Obesity is typically accompanied with diabetes. There is 
growing evidence suggesting that low NP levels might play a 
role in the development of future diabetes [34]. In contrast, 
established diabetes has been shown to increase BNP/NT-
proBNP levels [35], which is partially attributed to diabetes-
associated cardiac remodeling. Recent studies have shown 
that diabetes is an important extra-cardiac parameter that 
is associated with changes in BNP/NT-proBNP levels and 
that a high NT-proBNP level is a strong predictor of mor-
tality in patients with diabetes [35, 36]. Therefore, diabetes 
and body composition exert opposite effects on BNP and 
NT-proBNP changes, and the interpretation of NT-proBNP 
levels in diabetic and obese individuals is complicated. It is 
interesting to assess the influence of body composition on 
the NT-proBNP level and its prognostic performance in 
diabetic patients. Lunchner et  al. [37] demonstrated that 
baseline established diabetes, but not BMI, was indepen-
dently associated with changes in BNP/NT-proBNP levels 
Fig. 5 HRs of log NT‑proBNP levels considered as continuous variables for all‑cause mortality in the body composition subgroup of diabetic 
patients. The influence of body composition on the prognostic performance of the NT‑proBNP level for mortality is attenuated in the diabetic sub‑
groups. HR hazard ratio; NT-proBNP N‑terminal‑pro B‑type natriuretic peptide; BMI body mass index; LMI lean mass index; BF body fat
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during a 10-year follow-up. From a dynamic perspective, 
this finding indicates that the effect of longstanding diabe-
tes on the BNP/NT-proBNP level will gradually become 
greater than the effect of body composition on the BNP/
NT-proBNP level, which is a plausible explanation for our 
finding that diabetes attenuated the influence of body com-
position on the NT-proBNP level and its prognostic value. 
Unfortunately, we were unable to accurately evaluate the 
effect of diabetes duration on NT-proBNP changes in obese 
individuals, as data on the diabetes duration were unavail-
able. Future studies are needed to address this issue.
The present study had several limitations. First, 
although this study focuses on the relationship between 
body composition and NT-proBNP levels, body fat and 
lean mass were not directly measured. Thus, further stud-
ies in which lean mass and body fat are directly measured 
using methods, such as dual-energy X-ray absorptiom-
etry and bioelectrical impedance, are urgently needed. 
Nevertheless, the CUN-BAE equation has been derived 
from a large sample and validated in another large popu-
lation. Meanwhile, as direct measurement of BF and lean 
mass is rarely applied in clinical practice, assessment of 
body composition using equations, such as the CUN-
BAE equation, probably reflects the situation in a routine 
clinical setting. Second, despite the large sample size, the 
present study was a single-center observational study. 
Therefore, confounding factors could not be entirely 
avoided. Third, potential selection bias might have been 
present, as this is an inherent limitation of real-world 
studies. However, considering the relatively large sample 
size, the results were not likely to be by chance. Forth, 
the number of diabetic patients was small, and this might 
have cause the insufficient results. Further studies in 
a larger population are needed to overcome this issue. 
Fifth, the study population mainly included Chinese indi-
viduals, and thus, we cannot extrapolate the findings to 
other races/ethnicities. A previous study reported that 
the NT-proBNP levels vary across different races [38].
Conclusion
In a large population of  >1600 patients with ACS, we 
confirmed that BMI and LMI, but not BF amount, are 
inversely associated with NT-proBNP levels. Addition-
ally, the prognostic performance of this biomarker may 
be compromised in patients with high BMI, LMI, or BF. 
The influence of body composition on the NT-proBNP 
level and its prognostic performance might be attenuated 
in diabetic patients with ACS.
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